(S)-tert-butyl 4-(2,2-dibromovinyl)-2,2-dimethyloxazolidine-3-carboxylate | 130418-98-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (S)-tert-butyl 4-(2,2-dibromovinyl)-2,2-dimethyloxazolidine-3-carboxylate
• 英文别名: (S)-4-(2,2-dibromovinyl)-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester；(S)-4-(2,2-dibromo-vinyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester；tert-butyl (4S)-4-(2,2-dibromoethenyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
• CAS: 130418-98-3
• 化学式: C₁₂H₁₉Br₂NO₃
• 分子量: 385.096
• InChiKey: HRWWVECSXWNOOS-QMMMGPOBSA-N

物化性质

• 熔点：
  54-55 °C
• 沸点：
  388.3±42.0 °C(Predicted)
• 密度：
  1.591±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-tert-butyl 4-(2,2-dibromovinyl)-2,2-dimethyloxazolidine-3-carboxylate 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 乙基溴化镁 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 4.33h， 生成 (S)-tert-butyl 4-((2-formamidophenyl)ethynyl)-2,2-dimethyloxazolidine-3-carboxylate
  参考文献：
  名称：

  Tryprostatins A和B的全合成

  摘要：

  描述了三种不同的合成途径，它们连接到胰前列腺素的2-异戊二烯色氨酸核心骨架及其总合成物上。该策略包括传统的禾本科胺介导的偶联反应，Fürstner吲哚合成，以及我们由邻烯基苯基异氰酸酯进行的自由基介导的吲哚合成。通过低温自由基引发剂V-70（2,2'-偶氮二（4-甲氧基-2,4-二甲基戊腈））为吲哚进行自由基介导的结构的建立建立可靠的条件导致了Tryprostatins的高效合成A和B。

  DOI：

  10.1016/j.tet.2011.05.112
• 作为产物：
  描述：

  (R)-(+)-3-Boc-2,2-二甲基恶唑啉-4-甲醛 生成 (S)-tert-butyl 4-(2,2-dibromovinyl)-2,2-dimethyloxazolidine-3-carboxylate
  参考文献：
  名称：

  CHUNG, JOHN Y. L.;WASICAK, JAMES T., TETRAHEDRON LETT., 31,(1990) N8, C. 3957-3960

  摘要：

  DOI：

文献信息

• Stereoselective synthesis of (R)-(−)-2,2-dimethyl-3-t-butoxycarbonyl-4-ethynyl-oxazolidine: a chiral building block for the synthesis of a new class of substituted alkynes
  作者：Gianna Reginato、Alessandro Mordini、Alessandro Degl'Innocenti、Massimo Caracciolo

  DOI：10.1016/0040-4039(95)01725-w

  日期：1995.11

  (R)-(-)-2,2-Dimethyl-3-t-butoxycarbonyl-4-ethynyl-oxazolidine (3a) has been prepared in good yield from chiral aminoaldehyde (4) through a two step procedure. Metalation of compound (3a) and subsequent reaction with electrophiles has been investigated leading to the stereoselective synthesis of a new series of substituted alkynes which can be considered us useful precursors of compounds of biological

  （R）-（-）-2，2-二甲基-3-叔丁氧基羰基-4-乙炔基-恶唑烷（3a）已通过两步方法由手性氨基醛（4）以高收率制备。已经研究了化合物（3a）的金属化以及随后与亲电试剂的反应，导致立体选择性合成了一系列新的取代炔烃，这些被认为是有用的具有生物学意义的化合物的前体
• Total Synthesis of Tryprostatins A and B
  作者：Takayuki Yamakawa、Eiji Ideue、Jun Shimokawa、Tohru Fukuyama

  DOI：10.1002/anie.201004963

  日期：2010.11.22

  A reasonable approach to the radical: The establishment of reliable conditions for the radical‐mediated construction of indoles enabled the highly efficient synthesis of tryprostatins A and B. Use of the radical initiator 2,2′‐azobis(4‐methoxy‐2,4‐dimethylvaleronitrile) has allowed to carry out the radical cyclization at just 30 °C, thereby suppressing the formation of by‐products.

  自由基的合理方法：为吲哚进行自由基介导的构建建立可靠的条件，可以高效合成Tryprostatins A和B。自由基引发剂2,2'-偶氮二（4-甲氧基-2,4）的使用-二甲基戊腈）可以在30°C的温度下进行自由基环化，从而抑制了副产物的形成。
• 2-Aminooxazolines as TAAR1 ligands
  申请人：Galley Guido

  公开号：US20080261920A1

  公开（公告）日：2008-10-23

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及化合物I的公式，其中X，Y，R1，R2和n如本文所定义，或其药学上适宜的酸加盐。本发明还涉及含有这种化合物的制药组合物和治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神障碍、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病。
• 2-AMINOOXAZOLINES AS TAAR1 LIGANDS
  申请人：Galley Guido

  公开号：US20100120864A1

  公开（公告）日：2010-05-13

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中X，Y，R1，R2和n如本文所定义，或其药学适宜的酸加盐。本发明还涉及含有此类化合物的制药组合物，以及用于治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症，焦虑症，双相情感障碍，注意力缺陷多动障碍，应激相关障碍，精神疾病，精神分裂症，神经疾病，帕金森病，神经退行性疾病，阿尔茨海默病，癫痫，偏头痛，物质滥用和代谢性疾病，进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和吸收障碍，体温稳态障碍和功能障碍，睡眠和生物钟节律障碍以及心血管疾病。
• 2-aminooxazolines as TAAR1 ligands
  申请人：Galley Guido

  公开号：US08604061B2

  公开（公告）日：2013-12-10

  The invention relates to compounds of formula I wherein X, Y, R1, R2, and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中X、Y、R1、R2和n如本文所定义，或其药学上适宜的酸加盐。本发明还涉及含有这种化合物的制药组合物和治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症、焦虑症、躁郁症、注意力缺陷多动障碍、与压力相关的疾病、精神疾病、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病。